China Stem Cell Group Co Ltd partnered with Shanghai No 1 People's Hospital to successfully carry out umbilical cord stem cell transplantation for a 33-year-old female patient, according to Chongqing Stem Cell Technology Co Ltd on Nov 6,

Chongqing Stem Cell Technology Co Ltd, a subsidiary of China Stem Cell Group, is expected to have a storage of 200,000 stem cell samples, which will make it the biggest stem cell bank in Southwest China.

The company's Chongqing Cord Blood Bank has collected more than 20,000 samples of umbilical cord blood, umbilical cord mesenchymal stem cells and placenta-derived mesenchymal stem cells.

By the end of November this year, the bank located at Liangjiang New Area had provided 131 umbilical cord blood stem cells to 130 patients nationwide.

Workers at China Stem Cell Group Co Ltd go through information on umbilical cord blood stem cells. [Photo /liangjiang.gov.cn]

So far, umbilical cord stem cell transplantation has been considered as one of the most effective treatment against leukemia. Compared to bone marrow transplantation and peripheral blood stem cell transplantation, umbilical cord has advantages including abundant source, easy access, pure resource, light graft versus host reaction and low cost.

China Stem Cell Group Co.,Ltd. has clinical cooperation with more than 100 hospitals nationwide and offers umbilical cord stem cell transplantation for more than 800 patients every year.

The company has set up the biggest umbilical cord blood public resource bank in China. Patients can search for compatible sample online 24 hours and the matching rate is as high as 100 percent.